Generic Name and Formulations:
Naproxen 375mg, 500mg; e-c tabs.
- COPD Risk Predicted by Large Airway Dimensions on Computed Tomography
- Sleep Quality in COPD May Predict Overall Quality of Life
- Early-Onset Eczema May Increase Risk for Childhood Asthma
- Do Not Crush or Chew
- Pharmacological Effects of Alcohol with Medications
- Pharmacological Effects of Grapefruit Juice with Medications
Indications for EC-NAPROSYN:
Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. JRA.
Use lowest effective dose for shortest duration. Swallow whole. 375–500mg twice daily. Renal or hepatic impairment, elderly: consider lower doses.
<18yrs: not studied.
Aspirin allergy. Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Moderate-to-severe renal impairment (CrCl <30mL/min): not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (≥30 weeks gestation; avoid). Nursing mothers.
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Concomitant antacids, sucralfate, cholestyramine: not recommended. Serum levels increased by probenecid. May potentiate protein-bound drugs (eg, phenytoin, sulfonylureas, sulfonamides). May interfere with 5HIAA urinary assays or Porter-Silber tests.
NSAID (propionic acid deriv.).
GI upset, headache, dizziness, drowsiness, pruritus, tinnitus, edema, dyspnea; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions, anemia.
Tabs—100; Susp—473mL; EC—100